Securities Purchase Agreement (Details Textual) (USD $)	0 Months Ended			1 Months Ended	12 Months Ended		0 Months Ended	1 Months Ended			0 Months Ended						0 Months Ended	12 Months Ended			0 Months Ended				0 Months Ended			0 Months Ended
	Feb. 17, 2012	Jan. 19, 2012	May 26, 2010	Mar. 31, 2011	Dec. 31, 2013 Agreement	Dec. 31, 2012	May 26, 2010 Series C-2 Warrants [Member]	Mar. 31, 2011 Series C-2 Warrants [Member]	Mar. 31, 2011 Series C-2 Warrants [Member] Maximum [Member]	Mar. 31, 2011 Series C-2 Warrants [Member] Minimum [Member]	May 26, 2010 Series C-1 Preferred Stock [Member]	Sep. 24, 2013 Series C-1 Convertible Preferred Stock [Member]	Dec. 31, 2013 Series C-1 Convertible Preferred Stock [Member]	Sep. 23, 2013 Series C-1 Convertible Preferred Stock [Member]	Dec. 31, 2012 Series C-1 Convertible Preferred Stock [Member]	May 26, 2010 Series C-1 Convertible Preferred Stock [Member]	Sep. 24, 2013 Series C-2 Convertible Preferred Stock [Member]	Dec. 31, 2012 Series C-2 Convertible Preferred Stock [Member]	Dec. 31, 2013 Series C-2 Convertible Preferred Stock [Member]	May 26, 2010 Series C-2 Convertible Preferred Stock [Member]	May 26, 2010 Series D-1 Convertible Preferred Stock [Member]	Dec. 31, 2013 Series D-1 Convertible Preferred Stock [Member]	Dec. 31, 2012 Series D-1 Convertible Preferred Stock [Member]	May 26, 2010 Series D-2 Convertible Preferred Stock [Member]	Sep. 24, 2013 Series F Convertible Preferred Stock [Member]	Dec. 31, 2013 Series F Convertible Preferred Stock [Member]	Dec. 31, 2012 Series F Convertible Preferred Stock [Member]	May 26, 2010 Common Stock [Member]	Sep. 24, 2013 Private Placement [Member]	Sep. 24, 2013 Private Placement [Member] Series F Convertible Preferred Stock [Member]	Sep. 24, 2013 Private Placement [Member] Common Stock [Member]
Securities Purchase Agreement (Textual) [Abstract]
Securities purchase agreement, consideration received																															$ 10,000,000
Securities purchase agreement, number of shares issued																														3,250	1,928,620
Common stock, par value			$ 0.0001		$ 0.0001	$ 0.0001																									$ 0.0001
Securities purchase agreement, price per share																														$ 1,000	$ 3.50
Private placement commission cost																													300,000
Proceeds from issuance of derivative obligations			6,003,000																										9,700,000
Convertible preferred stock, conversion right cap, percent of common stock ownership																									9.99%
Convertible preferred stock, period of notice to increase or decrease conversion right cap																									61 days
Aggregate of common shares of company											5,134										5,134							5,794
Preferred stock, par value					$ 0.0001						$ 0.0001										$ 0.0001
Preferred stock, par value					$ 0.0001								$ 0.0001		$ 0.0001	$ 0.0001		$ 0.0001	$ 0.0001	$ 0.0001		$ 0.0001	$ 0.0001	$ 0.0001		$ 0.0001	$ 0.0001
Increased number of warrants							10,268		10,646	10,268
Preferred stock, shares authorized					8,000,000								11,000		11,000			22,000	0			0	5,134			10,000	10,000
Preferred stock, shares issued											5,134		7,016		5,792			500	0			0	4,615			3,250	0
Warrant, net proceeds					0	500,000												500,000
Proceeds from warrants, shares					500													500
Preferred stock, shares outstanding													7,016		5,792			500	0			0	4,615			3,250	0
Conversion of stock, shares converted																	557
Conversion of stock, shares issued												557
Cumulative dividends payable																			15.00%
Mandatory exercise of warrants upon achievement of the Preclinical Milestone								7,452,000
Mandatory exercise of warrants upon achievement of the Clinical milestone								3,194,000
Reverse stock split ratio	0.01	0.01
Securities Purchase Agreement (Additional Textual) [Abstract]
Percentage of investment of proceeds contributed by employee maximum			3.00%
Common stock, stated price			$ 150.00													$ 1,000
Exercise price series D1 warrants preferred			$ 1,000
Exercise price series C2 warrants preferred			1,000
Additional cash payment for right to receive Series C2 Preferred after milestones				236,000
Stockholders redemption period					12 months
Preferred Stock holders waived their 12-month redemption right and the requirement for the company to keep net cash					2,900,000
Preferred stock, liquidation preference price per share					$ 1,000
Preferred stock, liquidation preference													$ 7,016,000													$ 3,250,000
Extended Termination Date					3 years
Number of times company and purchasers entered into amendment agreements					2
Convertible preferred stock, conversion price												$ 0.5800		$ 0.2347											$ 3.5088